Home » Newsletters » BioWorld Science

BioWorld Science

July 22, 1999

View Archived Issues

Sitafloxacin: clinically useful fluoroquinolone

Licensing opportunity from the NIH: immunotoxins directed against malignant B-cells

Genset seeks patents for two genes associated with zileuton-induced hepatotoxicity

Licensing opportunity from NIH: broad-spectrum chemokine antagonist

Cerep and Bristol-Myers Squibb announce collaborative agreements

Viragen updates development programs

IDE granted to Gliatech for ADCON-A

Second quarter highlights summarized by SB

Tachykinin antagonists now proposed for attention deficit disorders

Water-soluble antitumor camptothecins reported by Japanese labs

Novel series of PDE4 inhibitors from Byk Gulden particularly useful for asthma prophylaxis

Inhibitors of Src family SH2 domains in early-stage development at Boehringer Ingelheim

Fujisawa investigators disclose dual adenosine A1/A2 receptor antagonists

New antiasthmatic agent in the pipeline at Nikken Chemicals

Aminomethylchromanes with potential for dyspepsia disclosed by Janssen

AstraZeneca claims new immunosuppressants for asthma, bronchitis, rhinitis, etc.

Roche summarizes financial and development highlights during first half of 1999

OraSolv Zomig receives first regulatory approval in Sweden for migraine

Antisense oligonucleotides specific for TS mRNA sequences enhance FdUrd cytotoxicity

Dosing discontinued in phase II MS trial of MSP-771

sNDA submitted for AmBisome for cryptococcal meningitis in AIDS patients

Ro-64-0796/GS-4104: potential drug interactions and beneficial effects in patients with the flu

New depsipeptides produced by sponges possess anti-HIV and antitumor effects

Molecular modeling yields new antiestrogenic and antitumor antineoplaston A10 analogues

Postischemic neuroprotective efficacy of LY-341122 reported at Brain '99

Brain '99: lanoteplase improves microcirculation in ischemic brain

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...